Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes

Press/Media

Period	1 Dec 2022

Media coverage

Title	Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes
Media name/outlet	Roche
Country/Territory	Switzerland
Date	1/12/22
URL	ct.moreover.com/?a=49393912252&p=1gw&v=1&x=IvulbYP9DpvzHgE6LnO8zw
Persons	Mauricio Burotto